Prospective randomized study of efficacy of trancatheter arterial chemoembolizaion with miriplatin for hepatocellular carcinoma
Phase 2
- Conditions
- Hepatocellular carcinoma
- Registration Number
- JPRN-UMIN000004790
- Lead Sponsor
- Kitasato University Scool of Medicine, Department of Gastroenterology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
Not provided
Exclusion Criteria
1) Vascular invasion or bile duct invasion. 2) Extrahepatic metastasis. 3) Major arterioportal shunt in the liver. 4) Combination with locoregional therapy. 5) Hepatic encephalopathy or refractory ascites. 6) Adjuvant therapy with IFN, Vit A or anti cancer drug. 7) Patients who have medical history of hypersensitivity of iodine or contrast media. 8) Patients who have severe thyroid disease. 9) Patients who are pregnant, lactating or are suspected to be pregnant. 10) Patients who are concluded to be inappropriate to participate in this study by their physicians.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Time to progression
- Secondary Outcome Measures
Name Time Method Response rate Safety Overall survival